Previous 10 | Next 10 |
- Inclisiran achieved 50% LDL-C lowering with time-adjusted reductions of 45% sustained over 18 months of treatment in patients with heterozygous familial hypercholesterolemia (HeFH) - ORION-9 further demonstrated inclisiran’s excellent safety profile, including no treatment-relate...
The Medicines Company (NASDAQ: MDCO ) is up 2% premarket on light volume in reaction to positive results from a Phase 3 clinical trial, ORION-10 , evaluating inclisiran, dosed twice per year, in patients with atheroslerotic cardiovascular disease and elevated low-density lipop...
This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn's Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn's regulatory 13F Form filed on 11/14/2019. Please visit our Tracking David Einhorn's Greenlight Capital Hol...
- Inclisiran achieved 58% LDL-C lowering with time-adjusted reductions of 56% sustained over 18 months of treatment in patients with atherosclerotic cardiovascular disease (ASCVD) - ORION-10 study affirmed inclisiran’s excellent safety profile, including no treatment-related liver ...
This article takes a look at the best-performing small-cap stocks with a list that presents an interesting group of emerging companies that are fast-growing or have attracted significant bullish sentiment based on a strong outlook. We take the Russell 2000 ( IWM ) constituents as our univers...
On their recent conference call for The Medicines Company ( MDCO ), management highlighted the power of Inclisiran’s profile and likelihood of its potential to change the paradigm of ASCVD (atherosclerotic cardiovascular disease) treatment, notes biotech expert John McCamant ...
Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...
ORION-10 presentation on November 16 and ORION-9 presentation on November 18 Company also to sponsor educational sessions throughout AHA annual meeting Company to host investor conference call and webcast on Monday, November 18, 12:00 pm EST, to discuss results of studies The...
Image source: The Motley Fool. Medicines Co (NASDAQ: MDCO) Q3 2019 Earnings Call Oct 30, 2019 , 8:30 a.m. ET Operator Continue reading
The Medicines Company (MDCO) Q3 2019 Earnings Conference Call October 30, 2019 8:30 AM ET Company Participants Krishna Gorti - Vice President of Investor Relations Mark Timney - Chief Executive Officer Christopher Visioli - Chief Financial Officer Peter Wijngaard - Chief Develo...
News, Short Squeeze, Breakout and More Instantly...
The Medicines Company Company Name:
MDCO Stock Symbol:
NASDAQ Market:
The Medicines Company Website:
The Medicines Company (the “Company”) today provided notice of a Make-Whole Fundamental Change to holders of its (i) 2.50% Convertible Senior Notes due 2022 (the “2022 Notes”), (ii) 2.75% Convertible Senior Notes due 2023 (the “2023 Notes”) and (ii) 3...
Shares of Meritor (NYSE: MTOR) , a global supplier of drivetrain, braking, and other aftermarket automotive solutions for vehicles, jumped as high as 16% Tuesday morning after markets digested the announcement that Meritor will join the S&P SmallCap 600 index. The announcement actually c...
NEW YORK , Dec. 30, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the open of trading on Monday, January 6 : NexPoint Residential Trust Inc. (NYSE: NXRT) will replace Avon Products Inc. (NYSE: AVP). Natura...